The 26th Developing Countries Vaccine Manufacturers Network (DCVMN) Annual General Meeting (AGM) officially opened. Held at The Meru, Sanur, Bali, from October 29 to 31, 2025, the prestigious forum is co-hosted by PT Bio Farma (Persero).
The event brings together more than 420 participants from 46 vaccine manufacturers across 17 developing countries, alongside multilateral organisations such as WHO, UNICEF, Gavi, CEPI, PATH, CHAI, and the Gates Foundation, as well as philanthropic partners, regulators, academics, and global health industry leaders. Under the theme “Advancing Innovation and Building a Resilient Vaccine Ecosystem for a Safer World,” the forum discusses strategies to strengthen vaccine production capacity, accelerate technology transfer, and expand access to safe, high-quality, and affordable vaccines for all.
Indonesia’s Minister of Health, Budi Gunadi Sadikin, in his virtual address, emphasised DCVMN’s critical role in strengthening the global vaccine ecosystem, particularly during the COVID-19 pandemic.
He highlighted that developing countries hold both great potential and a pivotal role in shaping the future of the global vaccine industry. Strengthening manufacturing capacity in these regions, he said, not only brings producers closer to their markets but also reinforces supply chains and creates sustainable long-term value.
“Thank you to the dedication of its members, DCVMN has redefined what global vaccine manufacturing looks like, expanding capacity, adopting new technologies, and forging strong partnerships,” he said.
Meanwhile, Indonesia’s Deputy Minister of Health, Dante Saksono Harbuwono, underscored the importance of innovation, R&D collaboration, and equitable access, including through initiatives such as the Vaccine Collaboration Centre and the Indonesia-China Joint Research and Development on Vaccines and Genomics Secretariat located in Kura-Kura, Bali.
“No country can act alone. Through DCVMN, let us advance deeper innovation and collaboration while ensuring equitable and timely access to vaccines for all,” Dante said.
“Indonesia continues to strengthen its R&D capabilities through the Vaccine Collaboration Centre, hosts the Indonesia-China Joint Research and Development on Vaccines and Genomics Secretariat in partnership with Tsinghua University, and participates in global clinical trials for TB and malaria, efforts that all contribute to our nation’s health sovereignty and the protection of every life.”
